Neurologists are very aware of Biogen’s newly approved Alzheimer’s drug, but few have prescribed it so far, a real-time study of the brand’s market launch has found.
The agency is considering whether to establish a national coverage policy for monoclonal antibody drugs that treat Alzheimer’s disease, including the newly approved drug aducanumab (Aduhelm).
The acting chief of the Food and Drug Administration has called for an investigation into the events leading up to the approval of Biogen’s brain plaque-clearing dementia drug aducanumab (Aduhelm).
The FDA’s new label restricts Aduhelm’s use to Alzheimer’s patients with mild cognitive impairment or mild dementia, drugmaker Biogen announced Thursday.
FDA approved Aduhelm earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness
“It is our responsibility to resist the urge to prescribe a potentially dangerous and ineffective medication that is untested in our population, even if it has FDA approval,” the LTC physician’s...
The true price to administer aducanumab — a controversial new Alzheimer’s treatment — may actually be closer to $100,000 annually than other, lower estimates and is just one reason the Centers for...
Please login or register first to view this content.